An interventional study of PrOMOTE in Hiv and Smoking, Cigarette, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Cigarette Smoking by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Cigarette Smoking · Medical University of South Carolina.
Among the 15 studies in Cigarette Smoking by Medical University of South Carolina, this one is the 4th largest by planned enrollment, is one of 3 that started in 2021, is one of 9 with no phase, and was the 9th registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →6 of the 15 studies in Cigarette Smoking by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 22–70 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 4 1
First in 2009; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 231 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 99 across the 15 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
5 of the studies in Cigarette Smoking by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06678789Medical University of South CarolinaEvaluation of Low and High Nicotine Tobacco Free Nicotine Pouches | 2027-01-01 |
| NCT05019495Medical University of South CarolinaOptimizing Tobacco Treatment Delivery for People Living With HIV | 2027-02-01 |
| NCT07625956Medical University of South CarolinaPiloting Novel Interventional Strategies to Improve Nicotine Pouches as a Substitute for Smoking | 2027-02-28 |
| NCT04903028Medical University of South CarolinaRTMS Targets Neural Circuits for Smoking Cessation | 2027-02-28 |
| NCT06373679Medical University of South CarolinaSwitch or Quit R01 | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Cigarette Smoking by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to conduct a randomized trial to evaluate a proactive, opt-out model of provider contact to deliver smoking cessation support for people living with HIV compared to standard care support delivered through traditional clinic pathways. Investigators will also evaluate implementation outcomes to identify barriers and facilitators towards future implementation. Investigators hope to define best practices and optimize the delivery of smoking cessation interventions for people living with HIV.
This hybrid effectiveness-implementation trial presents on opportunity to optimize tobacco treatment delivery for people living with HIV (PLWH), and identify barriers and facilitators towards future implementation. We are proposing a comparison of Treatment As Usual (TAU; reactive, opt-in tobacco treatment using standard clinical pathways) vs Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement (PrOMOTE). Participants will be randomized in a 1:1 allocation. The primary aim is to compare rates of cessation and quit attempts at the Week 12 follow-up between participants who received TAU versus PrOMOTE. As a secondary aim we will characterize key determinants of PrOMOTE reach, implementation fidelity, adherence, and acceptability. We hypothesize that the PrOMOTE intervention will increase cessation rates and number of quit attempts, and that it will result in greater reach and pharmacotherapy delivery compared to TAU. Key determinants of PrOMOTE implementation outcomes will also be characterized. An exploratory assessment of CD4 cell count and HIV viral load, in addition to durability of smoking cessation outcomes, will also be assessed. By optimizing the delivery of effective tobacco treatments for PLWH, we hope to increase the number of people receiving tobacco treatment, increase tobacco cessation rates, and reduce the risk of morbidity and mortality from smoking-related causes.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
This study's planned enrollment of 231 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Browse Cigarette Smoking studies →Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Compared within Cigarette Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment as Usual (TAU) participants will follow traditional clinic pathways for receiving tobacco treatment in the Medical University of South Carolina Health Infectious Disease outpatient clinic. All patients randomized to TAU will have the opportunity to access smoking cessation pharmacotherapy from the Infectious Disease clinical pharmacist.
In the PrOMOTE group, the participants will be contacted by the clinical pharmacist on the tobacco treatment staff three times for medication prescriptions and refills. They will also receive brief counseling and motivational interviewing by the clinical pharmacist.
Behavioral: PrOMOTE
This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
Also known as: Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement
Tobacco use abstinence
Self-reported and confirmed by breath carbon monoxide test
Time frame: 7 days
Reach
Percentage of current smokers engaged in an intervention
Time frame: 24 weeks (study completion)
Fidelity of intervention
The extent to which an intervention is implemented as intended. This will be collected via interviews with patients and providers.
Time frame: 24 weeks (study completion)
Fidelity of intervention
The extent to which an intervention is implemented as intended. This will be collected via surveys.
Time frame: 24 weeks (study completion)
Perceived barriers to the outcomes
Using the implementation tracking checklist, provider perceptions of barriers faced in completion of intervention steps will be monitored. These will be collected via interviews with patients.
Time frame: 24 weeks (study completion)
Perceived barriers to the outcomes
Using the implementation tracking checklist, provider perceptions of barriers faced in completion of intervention steps will be monitored. These will be collected via interviews with providers.
Time frame: 24 weeks (study completion)
Acceptability of intervention
The perception among stakeholders that the treatment is agreeable or satisfactory. This will be collected via interviews with patients and providers.
Time frame: 24 weeks (study completion)
Acceptability of intervention
The perception among stakeholders that the treatment is agreeable or satisfactory. This will be collected via surveys.
Time frame: 24 weeks (study completion)
Plan to share: No
Started Dec 2021 (actual). Primary completion is estimated for Feb 2027, 62 months after the start.
Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 62 months is above that.
Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →